pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Company profile
Ticker
SUPN
Exchange
Website
CEO
Jack Khattar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SUPERNUS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
MDD US Enterprises, LLC • MDD US Operations, LLC • Supernus Europe Ltd. • Adamas Pharmaceuticals, LLC • Adamas Operations, LLC • Adamas Holdings, LLC • Biscayne Neurotherapeutics, Inc. ...
SUPN stock data
Latest filings (excl ownership)
8-K
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial
24 Apr 24
8-K
Departure of Directors or Certain Officers
24 Apr 24
8-K
Supernus Provides Regulatory Update for SPN-830
8 Apr 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial
13 Feb 24
8-K
Other Events
5 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
Transcripts
SUPN
Earnings call transcript
2023 Q4
27 Feb 24
SUPN
Earnings call transcript
2023 Q3
8 Nov 23
SUPN
Earnings call transcript
2023 Q2
8 Aug 23
SUPN
Earnings call transcript
2023 Q1
9 May 23
SUPN
Earnings call transcript
2022 Q4
28 Feb 23
SUPN
Earnings call transcript
2022 Q3
8 Nov 22
SUPN
Earnings call transcript
2022 Q2
7 Aug 22
SUPN
Earnings call transcript
2022 Q1
10 May 22
SUPN
Earnings call transcript
2021 Q4
1 Mar 22
SUPN
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Padmanabh P. Bhatt
25 Mar 24
4
Padmanabh P. Bhatt
22 Mar 24
4
Padmanabh P. Bhatt
21 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
4
Padmanabh P. Bhatt
15 Mar 24
4
Padmanabh P. Bhatt
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Frank Mottola
29 Feb 24
4
Jack A. Khattar
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.99 mm | 94.99 mm | 94.99 mm | 94.99 mm | 94.99 mm | 94.99 mm |
Cash burn (monthly) | (no burn) | 1.38 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 9.46 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 85.53 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 62.2 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 235 |
Opened positions | 23 |
Closed positions | 35 |
Increased positions | 83 |
Reduced positions | 92 |
13F shares | Current |
---|---|
Total value | 1.55 tn |
Total shares | 56.65 mm |
Total puts | 1.90 k |
Total calls | 22.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 10.18 mm | $280.66 bn |
Vanguard | 6.07 mm | $167.41 bn |
Armistice Capital | 5.09 mm | $140.39 bn |
MCQEF Macquarie | 2.75 mm | $75.84 bn |
Dimensional Fund Advisors | 2.31 mm | $63.82 bn |
STT State Street | 1.92 mm | $52.85 bn |
Loomis Sayles & Co L P | 1.73 mm | $47.80 bn |
Stephens Investment Management | 1.70 mm | $47.00 bn |
Polar Capital | 1.65 mm | $45.61 bn |
Renaissance Technologies | 1.44 mm | $39.74 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 14,491 | 511.68 k | 8,570 |
21 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 14,491 | 366.62 k | 23,061 |
21 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 14,491 | 366.62 k | 12,745 |
20 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 400 | 14.12 k | 8,570 |
20 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 400 | 10.12 k | 8,970 |
20 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 400 | 10.12 k | 27,236 |
19 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 12,364 | 436.57 k | 8,570 |
19 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 12,364 | 312.81 k | 20,934 |
19 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 12,364 | 312.81 k | 27,636 |
13 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 33.48 | 36,116 | 1.21 mm | 8,570 |
News
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
8 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
Supernus Provides Regulatory Update For SPN-830, FDA Has Issued A CRL In Response To The Co's NDA For Spn-830 Indicating That The Review Cycle For The Application Is Complete, But That The Application Is Not Ready For Approval In Its Present Form.
8 Apr 24
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $41
28 Feb 24
Recap: Supernus Pharmaceuticals Q4 Earnings
27 Feb 24
Press releases
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
20 Apr 24
Supernus Provides Regulatory Update for SPN-830
8 Apr 24
Supernus to Participate in Two Upcoming Investor Conferences
6 Mar 24